In anticipation of launching its flagship Drug-Sensitivity Predictor, the Medical Prognosis Institute over the past month has secured funding for clinical trials, concluded licensing deals with software companies, and hired additional staff, according to a company official.
CEO and President Jesper Drejet told BioArray News last week that the firm is “definitely closer” to commercializing the technology, and that these preparatory steps will support the debut.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.